Vivani Medical
June 16, 2025
Company Presentation
Metabolic Diseases
Vivani Medical (Nasdaq: VANI) is an innovative, clinical-stage biopharmaceutical company developing miniature, ultra long-acting, GLP-1 drug implants by leveraging its proprietary NanoPortal platform technology. These highly-differentiated therapeutic implants are designed to deliver drug molecules steadily over extended periods with the goal of improving drug adherence and patient tolerability, which represent two main barriers to patients achieving the full potential benefits of GLP-1 therapy with the weekly injectable and daily oral pills on the market and in late-stage development today. Vivani’s pipeline includes NPM-139 (semaglutide) NPM-115 (exenatide) implants under development for chronic weight management with once or twice-yearly administration. The pipeline also includes implant candidates under development for type 2 diabetes and additional indications demonstrating GLP-1 benefits. Vivani's headquarters and dedicated GMP manufacturing facility are located in Alameda, CA.
Company HQ City:
Alameda
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2011
Lead Product in Development:
NPM-115 (GLP-1 implant)
CEO
Adam Mendelsohn, PhD
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
3
Exchange
Nasdaq
Ticker
VANI
When you expect your next catalyst update?
Mid 2025 - NPM-115 Phase 1 data read-out
What is your next catalyst (value inflection) update?
Mid 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}